Carcinoma-associated fibroblasts affect sensitivity to oxaliplatin and 5FU in colorectal cancer cells

dc.contributor.authorGonçalves-Ribeiro, Samuel
dc.contributor.authorGuillén Díaz-Maroto, Natalia
dc.contributor.authorBerdiel Acer, Mireia
dc.contributor.authorSoriano Izquierdo, Antonio
dc.contributor.authorGuardiola, Jordi
dc.contributor.authorMartínez Villacampa, Mercedes
dc.contributor.authorSalazar Soler, Ramón
dc.contributor.authorCapellá, G. (Gabriel)
dc.contributor.authorVillanueva Garatachea, Alberto
dc.contributor.authorMartínez Balibrea, Eva
dc.contributor.authorMolleví, David G.
dc.date.accessioned2021-06-22T14:59:31Z
dc.date.available2021-06-22T14:59:31Z
dc.date.issued2016-09-13
dc.date.updated2021-06-22T14:59:31Z
dc.description.abstractThe importance of tumor microenvironment (TME) as a relevant contributor to cancer progression and its role in the development of de novo resistance to targeted therapies has become increasingly apparent. However, the mechanisms of microenvironment-mediated drug resistance for nonspecific conventional chemotherapeutic agents, such as platinum compounds or antimetabolites, are still unclear. Here we describe a mechanism induced by soluble factors released by carcinoma-associated fibroblasts (CAFs) that induce the translocation of AKT, Survivin and P38 to the nucleus of tumor cells. These changes are guided to ensure DNA repair and the correct entrance and exit from mitosis in the presence of chemotherapy. We used conditioned media (CM) from normal-colonic fibroblasts and paired CAFs to assess dose response curves of oxaliplatin and 5-fluorouracil, separately or combined, compared with standard culture medium. We also evaluated a colony-forming assay and cell death to demonstrate the protective role of CAF-CM. Immunofluorescence confirmed the translocation of AKT, P38 and Survivin to the nucleus induced by CAF-soluble factors. We also have shown that STAT3 or P38 inhibition provides a promising strategy for overcoming microenvironment-mediated resistance. Conversely, pharmacologic AKT inhibition induces an antagonistic effect that relieves a cMET and STAT3-mediated compensatory feedback that might explain the failure of AKT inhibitors in the clinic so far.
dc.format.extent15 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec687441
dc.identifier.issn1949-2553
dc.identifier.pmid27517495
dc.identifier.urihttps://hdl.handle.net/2445/178653
dc.language.isoeng
dc.publisherImpact Journals
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.18632/oncotarget.11121
dc.relation.ispartofOncotarget, 2016, vol. 7, num. 37, p. 59766-59780
dc.relation.urihttps://doi.org/10.18632/oncotarget.11121
dc.rightscc-by (c) Gonçalves-Ribeiro, Samuel et al., 2016
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Ciències Clíniques)
dc.subject.classificationFibroblasts
dc.subject.classificationCàncer
dc.subject.classificationFarmacologia
dc.subject.classificationMetabolisme
dc.subject.otherFibroblasts
dc.subject.otherCancer
dc.subject.otherPharmacology
dc.subject.otherMetabolism
dc.titleCarcinoma-associated fibroblasts affect sensitivity to oxaliplatin and 5FU in colorectal cancer cells
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
687441.pdf
Mida:
9.88 MB
Format:
Adobe Portable Document Format